Kerry Flynn of Axios spoke with Matt Fottrell, vice president of the Financial Times in the U.S. and managing director of FT Specialist, about its majority stake purchase in biotech news site Endpoints News.
Flynn writes, “Speaking from the FT’s New York office in the west side of Soho, Fottrell says the deal with Endpoints made sense given the publication’s editorial mission aligned with its own.
- “‘The biopharma sector’s a multitrillion-dollar industry. It’s highly regulated. It’s incredibly competitive. There’s always deals taking place … and they are news hungry,’ Fottrell says.
- ‘Broadly speaking, I like businesses where there’s a prize for winning and a penalty for losing,’ he adds. ‘That makes [people] more likely to subscribe.'”
To read more, go here.
